• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,645
107
73
69
69

COUNTRY

68
21
17
11
10

CATEGORIES

  • 576
  • 122
  • 558
  • 80
  • 530
  • 43
  • 507
  • 17
  • 19
  • 25

PRICE

813
1,113
1,311
2,779

PUBLISHED

180
274
672
2,779

PRODUCT TYPE

2,204
495
68
7
2
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-9 signaling pathway activates Jak/STAT and MAPK signaling modules. There are today 61 companies plus partners developing 64 IL-9 pathway targeting drugs in 251 developmental projects in cancer....

March 2014
Colorectal Cancer Drug Pipeline Update 2014 Colorectal Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Colorectal Cancer Drug Pipeline Update 2014

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of...

March 2014
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The androgen receptor signaling pathway activates the SMAD signaling module. There are today 327 companies plus partners developing 426 Androgen Receptor drugs in 1397 developmental projects in cancer....

March 2014
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

Activation of the B cell receptor involves phosphorylation of the cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs) present in Ig alpha and beta. This leads to activation of several...

March 2014
TSH Signaling Pathway in Oncology Drug Pipeline Update 2014 TSH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TSH Signaling Pathway in Oncology Drug Pipeline Update 2014

Human thyroid stimulating hormone (TSH) exerts its action through various signaling cascades such as cAMP cascade and the phospholipase C beta-mediated inositol phosphate generation. Further, it will...

March 2014
Proteins in Oncology Drug Pipeline Update 2014 Proteins in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Proteins in Oncology Drug Pipeline Update 2014

This drug pipeline update covers proteins, excluding antibodies, as drugs for the treatment of cancer. There are today 322 companies plus partners developing 355 protein drugs in 661 developmental...

March 2014
TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The TGF-beta receptor signaling pathway activates the MAPK/SMAD signaling modules. There are today 288 companies plus partners developing 403 TGF-beta receptor pathway targeting drugs in 1356 developmental...

March 2014
Biologicals in Oncology Drug Pipeline Update 2014 Biologicals in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Biologicals in Oncology Drug Pipeline Update 2014

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1620...

March 2014
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-4 signaling pathway stimulates the JAK/STAT and MAPK signaling modules. There are today 144 companies plus partners developing 209 IL-4 pathway targeting drugs in 697 developmental projects...

March 2014
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-2 signaling pathway activates the Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules. There are today 239 companies plus partners developing 360 IL-2 pathway targeting drugs in 1260...

March 2014
Epigenetic Therapy in Oncology Drug Pipeline Update 2014 Epigenetic Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Epigenetic Therapy in Oncology Drug Pipeline Update 2014

Improper gene activation or silencing by loss of epigenetic control can lead to aberrant gene expression that can drive the development of diseases such as cancer, autoimmunity, diabetes, or neurological...

March 2014
Renal Cancer Drug Pipeline Update 2014 Renal Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Renal Cancer Drug Pipeline Update 2014

The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being...

March 2014
Neuroendocrine Tumors Drug Pipeline Update 2014 Neuroendocrine Tumors Drug Pipeline Update 2014 - Product Thumbnail Image

Neuroendocrine Tumors Drug Pipeline Update 2014

There are today 78 companies plus partners developing 85 neuroendocrine tumor drugs in 124 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount...

March 2014
Radiation Therapy in Oncology Drug Pipeline Update 2014 Radiation Therapy in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Radiation Therapy in Oncology Drug Pipeline Update 2014

This drug pipeline update is structured around radiolabeled drugs, radiosensitizers and radioprotective compounds. There are today 319 companies plus partners developing 335 radiation therapy drugs...

March 2014
Melanoma Drug Pipeline Update 2014 Melanoma Drug Pipeline Update 2014 - Product Thumbnail Image

Melanoma Drug Pipeline Update 2014

Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced...

March 2014
Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014 Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Chemokine Signaling Pathway in Cancer Drug Pipeline Update 2014

Inflammatory immune response requires the recruitment of leukocytes to the site of inflammation upon foreign insult. Chemokines are small chemoattractant peptides that provide directional cues for the...

March 2014
Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014 Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2014

Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the...

March 2014
Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014 Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2014

Cell adhesion molecules are (glyco)proteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis,...

March 2014
Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Calcium Signaling Pathway in Cancer Drug Pipeline Update 2014

There are today 159 companies plus partners developing 203 calcium signaling pathway targeting drugs in 799 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated...

March 2014
Gap Junctions in Oncology Drug Pipeline Update 2014 Gap Junctions in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Gap Junctions in Oncology Drug Pipeline Update 2014

Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels',...

March 2014
Loading Indicator

Our Clients

Our clients' logos